activation in response to high glucose require caveolin-1 phosphorylation in mesangial cells. Am J Physiol Renal Physiol 306: F1308-F1317, 2014. First published April 2, 2014 doi:10.1152/ajprenal.00447.2013.-Glomerular matrix accumulation is a hallmark of diabetic renal disease. Serine/threonine kinase PKC-␤1 mediates glucose-induced Akt S473 phosphorylation, RhoA activation, and transforming growth factor (TGF)-␤1 upregulation and finally leads to matrix upregulation in mesangial cells (MCs). It has been reported that glucose-induced PKC-␤1 activation is dependent on caveolin-1 and the presence of intact caveolae in MCs; however, whether activated PKC-␤1 regulates caveolin-1 expression and phosphorylation are unknown. Here, we showed that, although the caveolin-1 protein level had no significant change, the PKC-␤-specific inhibitor LY-333531 blocked caveolin-1 Y14 phosphorylation in high glucose (HG)-treated MCs and in the renal cortex of diabetic rats. The Src-specific inhibitor SU-6656 prevented the HG-induced association between PKC-␤1 and caveolin-1 and PKC-␤1 membrane translocation, whereas PKC-␤1 small interfering RNA failed to block Src activation, indicating that Src kinase is upstream of PKC-␤1 activation. Although LY-333531 blocked PKC-␤1 membrane translocation, it had no effect on the PKC-␤1/ caveolin-1 association, suggesting that PKC-␤1 activation requires the interaction of caveolin-1 and PKC-␤1. PKC-␤1-mediated Akt S473 phosphorylation, RhoA activation, and fibronectin upregulation in response to HG were prevented by SU-6656 and nonphosphorylatable mutant caveolin-1 Y14A. In conclusion, Src activation by HG mediates the PKC-␤1/caveolin-1 association and PKC-␤1 activation, which assists in caveolin-1 Y14 phosphorylation by Src kinase. The downstream effects, including Akt S473 phosphorylation, RhoA activation, and fibronectin upregulation, require caveolin-1 Y14 phosphorylation. Caveolin-1 is thus an important mediator of the profibrogenic process in diabetic renal disease. extracellular matrix; glomerular sclerosis; caveolin-1 phosphorylation
HYPERGLYCEMIA IS THE MAJOR RISK FACTOR responsible for the development and progression of diabetic renal disease. Elevated glucose concentrations affect numerous pathways thought to contribute to the pathogenesis of diabetic kidney injury (13, 31) . These include the activation of PKCs, in particular, the PKC ␤-isoform. Several studies (15, 18, 27) have suggested the important role of PKC-␤ in the pathophysiology of diabetic renal disease. Both PKC-␤ inhibition and PKC-␤ deletion prevented glomerular matrix accumulation and the development of diabetic renal disease (1, 19, 26, 34, 37) . Because activation of PKC-␤2 is not observed in mesangial cells (MCs) and PKC-␤2 is undetectable in glomeruli in vivo (17, 41, 44) , PKC-␤1 activation plays an essential role in glomerular matrix elaboration.
Caveolae are unique vesicular organelles (50 -100 nm in diameter) found in the plasma membrane of many cell types (43) , including MCs (54) . Caveolin-1 is the major protein component of caveolae and acts as a scaffold or platform for many molecules involved in signal transduction (42, 51) . It has been reported that caveolae and caveolin-1 play important roles in high glucose (HG)-induced PKC-␤1 activation (65) . However, whether activated PKC-␤1 regulates caveolin-1 expression and phosphorylation in MCs has not yet been addressed.
Glomerular matrix accumulation is the pathological hallmark of diabetic renal disease (16, 32, 49) . The serine/threonine kinase PKB (Akt) has emerged as an important mediator of matrix upregulation in response to numerous stimuli, including glucose and transforming growth factor (TGF)-␤1 (45, 58, 62) . We (58) have previously shown that collagen type I induction by HG requires the activation of Akt. Akt activation requires membrane translocation and phosphorylation on two sites, T308 and S473 (12) . At the membrane, Akt is phosphorylated at T308 by phosphoinositide-dependent protein kinase-1 (6) . There have been several S473 kinases identified in different cells and stimulus. We (59) have previously shown that PKC-␤1 functions as an Akt S473 kinase in response to HG in MCs and demonstrated that PKC-␤ inhibition with ruboxistaurin prevents Akt phosphorylation of S473 in diabetic kidneys. Although PKC-␤1 is a glucose-induced Akt S473 kinase, the involvement of some cofactors cannot be excluded because the activity assays were performed with PKC-␤1 immunoprecipitated from MCs. The present study sought to investigate whether HG-induced PKC-␤1 activation regulates caveolin-1 expression and phosphorylation both in vitro and in animal models and to study the relationship between caveolin-1 and PKC-␤1 in the pathogenesis of diabetic kidney disease. We further explored the role of caveolae and caveolin-1 in PKC-␤1-mediated Akt phosphorylation of S473 in MCs in response to HG.
RhoA, a member of the Rho small G protein family, is highly expressed in the renal cortex (3, 4) . Several recent studies (14, 33, 52, 53) have proposed that RhoA/Rho kinase may play an important role in renal fibrosis by mediating multiple intracellular signaling pathways involving TGF-␤, ANG II, and NF-B. Furthermore, RhoA pathway inhibition ameliorates the progression of diabetic nephropathy (2, 11, 20, 22, 40) , suggesting an important role of RhoA signaling in the development of glomerular matrix accumulation and diabetic kidney disease. It has been previously reported that RhoA activation in response to HG requires intact caveolae in MCs (65) . Whether caveolin-1 phosphorylation is involved in HGinduced RhoA activation has not yet been studied. Hence, we also investigated whether HG-induced RhoA activation is dependent on caveolin-1 phosphorylation. This may broaden our understanding of diabetic glomerulosclerosis signaling pathways, further allowing us to find a new strategy for the prevention and treatment of diabetic kidney disease.
MATERIALS AND METHODS
Cell culture. Sprague-Dawley primary MCs were obtained from glomeruli of rats (Animal Center of Wuhan University) by differential sieving and cultured in DMEM supplemented with 20% FCS (Invitrogen), streptomycin (100 g/ml), and penicillin (100 U/ml) at 37°C in 95% air and 5% CO 2. Experiments were carried out using cells between passages 6 and 15. The medium contained 5.6 mM glucose. Either 24.4 mM glucose (final concentration: 30 mM) or mannitol (24.4 mM) was added for HG levels or the osmotic control, respectively. Confluent MCs were made quiescent by serum deprivation for 24 h before treatment. The following pharmacological inhibitors were added before HG treatment: LY-333531 (Calbiochem), 200 nM for 60 min; cyclodextrin (Calbiochem), 5 mM for 60 min; filipin III (Sigma), 2.5 g/ml for 10 min; cholesterol (Sigma), 15 g/ml for 60 min; SU-6656 (Sigma), 10 M for 30 min; and wortmannin (Sigma), 100 nM for 60 min.
Protein extraction and analysis. Cells or kidney cortexes were lysed and protein extracted as previously described (28) . Briefly, cell lysates were collected and centrifuged at 4°C and 14,000 rpm for 10 min to pellet cell debris. The supernatant (50 g) was separated using SDS-PAGE, and Western blot analysis was performed. The antibodies used included monoclonal caveolin-1 (1:1,000, Upstate), monoclonal phospho-caveolin-1 Y14 (1:1,000, BD Biosciences), monoclonal PKC-␤1 (1:1,000, Santa Cruz Biotechnology), polyclonal phosphoAkt S473 (1:1,000, Cell Signaling), polyclonal Akt (1:1,000, Cell Signaling), polyclonal phospho-Src Y416 (1:1,000, Cell Signaling), polyclonal Src (1:1,000, Cell Signaling), monoclonal RhoA (1:500, Santa Cruz Biotechnology), monoclonal fibronectin (1:5,000, BD Biosciences), and monoclonal ␤-actin (1:5,000, Sigma).
For immunoprecipitation experiments, cells or kidney cortexes were harvested in lysis buffer that included 60 mM N-octyl-glucopyranoside (28) . After clarification, equal amounts of lysate were incubated overnight with 2 g of primary antibody under rotation at 4°C followed by 25 l of protein G-agarose slurry for 1.5 h at 4°C. Immunoprecipitates were extensively washed, resuspended in 2ϫ sample buffer, boiled, and analyzed by immunoblot analysis.
For cytosol-membrane fractionation, cells were lysed with hypotonic lysis buffer (59) . Lysates were homogenized by 25-gauge needle passage and centrifuged at 100,000 g for 60 min. The supernatant was taken as the cytosol, and the pellet was resuspended in regular lysis buffer including 60 mM N-octyl-glucopyranoside. After centrifugation at 100,000 g for 60 min, the supernatant was collected as the membrane fraction.
RhoA pulldown assay. RhoA pulldown was performed as previously described (28) . MCs were lysed in hypertonic buffer, and GTP-bound RhoA was immunoprecipitated from the cleared lysate with 25 l of glutathione-S-transferase-tagged rhotekin-RhoA-binding domain bound to glutathione-agarose (Cytoskeleon). Beads were washed, and the immunoprecipitate was resolved with 15% SDS-PAGE. Membranes were probed with monoclonal anti-RhoA antibody (1:500, Santa Cruz Biotechnology). The lysate (40 g) was also probed for RhoA to ensure equality across conditions.
Transfection. NH 2-terminal enhanced green fluorescent protein (EGFP)-tagged Cav-1Y14A was used for transfection, and MCs were transfected as previously described (61) . Rat MCs were grown to 50 -60% confluence and transiently transfected with empty vector or pEGFP-Cav-1Y14A using Effectene (Qiagen) according to the manufacturer's instructions. After 24 h, MCs were serum deprived for 24 h and the experiments proceeded.
RNA interference. Rat PKC-␤1 small interfering (si)RNA and control nontargeting siRNA were purchased from RiboBio. MCs were transfected with 100 nM siRNA using Effectene (Qiagen) at 50 -60% confluence. At 18 -24 h posttransfection, the medium was changed to 0% FCS for 24 h. MCs were then treated with HG for 1 h, and the cell lysate was harvested as described above. Immunoblot analysis of the PKC-␤1 protein expression level was used to assess the efficacy of downregulation by RNA interference.
Animal experiments. Experiments were performed with male Sprague-Dawley rats weighing 200 -225 g (Animal Center of Wuhan University) in accordance with official recommendations of Chinese Community Guidelines. Diabetes was induced with a 55 mg/kg streptozotocin (STZ; Sigma) injection into the tail vein. Control rats received equal volume of 0.1 M citrate buffer (pH 4.5). Hyperglycemia (blood glucose Ͼ 20 mM) was confirmed 3 days after the injection using a reflectance meter (One Touch, Lifescan, Milpetas, CA). Diabetic rats were randomized to receive the PKC-␤-specific inhibitor LY-333531 (10 mg·kg Ϫ1 ·day Ϫ1 , Sigma) by gavage feeding 48 h after induction. Control rats were fed equal volumes of water. All rats had free access to regular lab chow and water. Diabetic rats also received a low dose of insulin if required to prevent ketonuria as assessed by dipstick (Bayer Multistix) but to maintain hyperglycemia Ͼ 20 mM. Treatment was continued for 4 wk, urine was collected for 24 h in a metabolic cage at the end of the study and weight, and blood glucose levles were obtained. Serum or urine creatinine and urine albumin were measured using Roche kits on a Modular P analyzer. The creatinine clearance rate was calculated as follows: creatinine clearance rate (in ml/min) ϭ urine creatinine ϫ urine volume (in ml/min)/serum creatinine. Rats were then anesthetized for kidney removal. Renal hypertrophy was assessed by the kidney weight-tobody weight ratio (in mg/g) at the time of death. Protein was extracted from the isolated cortex for Western blot analysis.
Statistical analysis. Data are presented as means Ϯ SE. Statistical analysis was performed by one-way ANOVA with a Turkey honest significant difference test for post hoc analysis for experiments (SPSS 17.0 for Windows). P values of Ͻ0.05 were considered significant. Experiments were repeated multiple times, and the number of repetitions (n) is given in the figures.
RESULTS

PKC-␤1 is involved in HG-induced caveolin-1 phosphorylation in MCs.
It has been previously shown that HG increased the protein level of caveolin-1 in bovine aortic endothelial cells (55) . However, no studies have yet addressed whether HG regulates caveolin-1 expression and phosphorylation in MCs. In the present study, primary rat MCs were treated with 30 mM glucose for the times indicated, and caveolin-1 protein levels and phosphorylation of Y14 were measured by Western blot analysis. A time-dependent increase in phosphorylation on Y14 was observed, which was significant by 10 min. Although there was a trend toward increased caveolin-1 protein levels after HG treatment, this was not statistically significant (Fig. 1A) .
We then assessed the potential role of PKC-␤1 in HGinduced caveolin-1 phosphorylation of Y14. The PKC-␤-specific inhibitor LY-333531 was used, which can prevent ATP binding to the active site of PKC-␤, thereby inhibiting its ability to phosphorylate substrates (1) . Figure 1B showed that LY-333531 blocked caveolin-1 phosphorylation on Y14 induced by HG, which was significant by 200 nM. However, PKC-␤ inhibition had no effect on caveolin-1 expression (Fig.  1C) . Since PKC-␤2 is not activated by glucose in MCs (17, 41, 44), these results indicate that PKC-␤1 activation may involve HG-induced caveolin-1 phosphorylation of Y14.
PKC-␤ inhibition in vivo prevents caveolin-1 phosphorylation in diabetic rat kidneys. Caveolae and caveolin-1 play important roles in the pathogenesis of diabetes mellitus (5, 8, 30) , but their roles in the development of diabetic renal disease are currently little known. We therefore determined caveolin-1 protein and phosphorylation levels in diabetic kidneys and then tested whether PKC-␤1 plays a role in caveolin-1 phosphorylation in vivo. Type 1 diabetes was induced in Sprague-Dawley rats by STZ injection. A group of diabetic rats was treated with the PKC-␤ inhibitor LY-333531 (10 mg/kg daily) as previously described (18) . After 4 wk, diabetic rats had significantly higher blood glucose levels than their nondiabetic counterparts, which were unaffected by LY-333531. Diabetic rats developed renal hypertrophy, as evidenced by a significantly higher kidney weight-to-body weight ratio. This was decreased by LY-333531. Increased albumin excretion, a hallmark of early diabetic nephropathy, was observed in the diabetic group and attenuated by LY-333531. The increased creatinine clearance rate in the diabetic group was also improved by LY-333531 (Table 1) . PKC-␤1 translocation to the membrane was assessed by immunoblot analysis, which represents PKC-␤1 activation. As shown in Fig. 2A , LY-333531 prevented PKC-␤1 membrane translocation in diabetic rats. Figure 2B shows that phosphorylated caveolin-1 on Y14 significantly increased in the kidney cortex of diabetic rats. Although total protein levels of caveolin-1 increased in diabetic kidney cortexes, this was not statistically significant. Treatment with LY-333531 prevented caveolin-1 phosphorylation of Y14 and had no effect on caveolin-1 protein levels. These data further support the role of PKC-␤ in caveolin-1 phosphorylation in vivo.
HG induces the binding of PKC-␤1 and caveolin-1. Since PKC-␤1 plays an important role in caveolin-1 phosphorylation of Y14, we next sought to determine the physical association between PKC-␤1 and caveolin-1. As shown in Fig. 3A , Fig. 1 . PKC-␤ inhibitor prevents high glucose (HG)-induced caveolin (Cav)-1 Y14 phosphorylation. A: serum-deprived mesangial cells (MCs) were treated with 30 mM glucose (HG) for the indicated times, and Cav-1 phosphorylation of Y14 (pCav-1Y14) and Cav-1 protein levels were assessed by Western blot analysis, with actin used as a loading control (n ϭ 6). *P Ͻ 0.05 vs. control. B: MCs were pretreated for the indicated concentrations with the specific PKC-␤ inhibitor LY-333531 (LY) before treatment with HG for 1 h, and Cav-1 phosphorylation of Y14 was assessed by Western blot analysis (n ϭ 6). *P Ͻ 0.05 vs. control. C: pretreatment with LY (200 nM, 1 h) prevented Cav-1 Y14 phosphorylation but had no effect on Cav-1 protein levels (n ϭ 5). *P Ͻ 0.05, HG-treated group vs. the other groups. PKC-␤1 protein was detected in anti-caveolin-1 immunoprecipitates after HG treatment. Similarly, caveolin-1 was observed in anti-PKC-␤1 immunoprecipitates after HG treatment (Fig. 3B) . Although the PKC-␤-specific inhibitor LY-333531 blocked PKC-␤1 membrane translocation ( Fig. 2A) , it had no effect on the PKC-␤1/caveolin-1 association (Fig. 3, A and B) , suggesting that PKC-␤1 activation requires the interaction of caveolin-1 and PKC-␤1. As shown in Fig. 3C , caveolin-1 phosphorylated on Y14 was immunoprecipitated with PKC-␤1 after HG treatment, which was dependent on PKC-␤1 activation because it was blocked by LY-333531. This supports the possibility of PKC-␤1 being involved in HG-induced caveolin-1 phosphorylation of Y14. To assess this possibility more conclusively, we used RNA interference to downregulate PKC-␤1. Figure 3D shows the successful downregulation of PKC-␤1 protein by RNA interference. Caveolin-1 phosphorylation of Y14 was abrogated by PKC-␤1 downregulation (Fig.  3D ). This further suggests that PKC-␤1 is involved in caveolin-1 phosphorylation of Y14 in response to HG in MCs.
PKC-␤1/caveolin-1 association and PKC-␤1 membrane translocation require Src activation. Although PKC-␤1 is involved in caveolin-1 phosphorylation of Y14 in response to HG in MCs, the mechanism is still unknown. Caveolin-1 is a substrate of the Src family kinases (7, 29, 47) , and we (40, 61) have previously shown that VEGF-or TGF-␤-induced caveolin-1 phosphorylation of Y14 is mediated by Src kinases in MCs. We thus assessed the role of Src in the context of HG stimulation. MCs were treated with 30 mM glucose for the Fig. 2 . PKC-␤ inhibition prevents Cav-1 Y14 phosphorylation in diabetic kidneys. Type 1 diabetic Sprague-Dawley rat kidney cortexes were analyzed 4 wk after the onset of diabetes. One group was treated with LY (10 mg/kg daily). A: Western blots of renal cortical membrane fractions showing the significant increase in PKC-␤1 protein levels in diabetic animals, which was blocked by LY (n ϭ 10). The following groups are shown: control (C), streptozotocin (STZ) treatment (S), and STZ ϩ LY treatment. *P Ͻ 0.05, STZ-treated group vs. the other groups. B: Western blots of cortical protein demonstrating the significant increase in Cav-1 Y14 phosphorylation in diabetic animals, which was prevented by LY (n ϭ 10). *P Ͻ 0.05, STZ-treated group vs. the other groups. Cav-1 protein levels, however, were unaffected in diabetic rats or by treatment with LY. Fig. 3 . Cav-1 Y14 phosphorylation by HG requires association with PKC-␤1. MCs were pretreated with LY (200 nM, 1 h) before HG treatment for 1 h. A: after immunoprecipitation (IP) of Cav-1, PKC-␤1 protein levels were assessed by Western blot [immunoblot (IB)] analysis. HG led to an association between Cav-1 and PKC-␤1, and this was independent of PKC-␤1 activity (n ϭ 5). *P Ͻ 0.05 vs. control. B: after immunoprecipitation of PKC-␤1, Western blot analysis for Cav-1 was performed. Similarly, HG induced an association of PKC-␤1 and Cav-1 that was independent of PKC-␤1 activity (n ϭ 4). *P Ͻ 0.05 vs. control. C: HG led to an association of PKC-␤1 with Cav-1 phosphorylated on Y14, and this was dependent on PKC-␤1 activation (n ϭ 5). *P Ͻ 0.05, HG-treated group vs. the other groups. D: MCs were transfected with PKC-␤1 RNA interference (RNAi) or control RNAi (ConRNAi) to downregulate the expression of PKC-␤1. RNAi significantly decreased PKC-␤1 protein levels and prevented Cav-1 Y14 phosphorylation in response to HG (n ϭ 4). *P Ͻ 0.05 vs. control. indicated times, and autophosphorylation of Y416 on Src was assessed by immunoblot analysis, which represents increased Src activity. As shown in Fig. 4A , Src autophosphorylation was seen by 10 min and sustained to 1 h.
Src and its related kinases localize to caveolae in numerous cell types, including MCs (39, 43) . We next observed whether Src activation is dependent on intact caveolae. The membraneimpermeable cholesterol-binding agent cyclodextrin can deplete cell surface cholesterol, and the membrane-permeable agent filipin III can perturb the formation of caveolae (50, 56) . Figure 4B shows that chemical disruption of caveolae with cyclodextrin or filipin did not prevent Src activation, suggesting that HG-induced Src activation is caveolae independent. We then asked whether HG-induced caveolin-1 phosphorylation was mediated by Src in MCs. Figure 4C shows that the Src-specific inhibitor SU-6656 (10 M) prevented caveolin-1 phosphorylation of Y14 after HG treatment and had no effect on caveolin-1 expression. SU-6656 also blocked the association between PKC-␤1 and caveolin-1 as well as PKC-␤1 membrane translocation induced by HG (Fig. 4, D and E) . Figure 4F shows that downregulation of PKC-␤1 protein by RNA interference had no effect on Src activation. Taken together, these results suggest that Src activation is the upstream event in HG-induced PKC-␤1/caveolin-1 association and PKC-␤1 activation, which then mediates caveolin-1 Y14 phosphorylation.
Caveolin-1 is involved in Akt activation. We first examined the effects of caveolar disruption on HG-induced Akt activation. As shown in Fig. 5A , chemical disruption of caveolae with cyclodextrin or filipin prevented Akt activation. This demonstrates that intact caveolae are required for HG-induced Akt activation. We then examined whether Src inhibition MCs were treated with HG in the presence or absence of pretreatment with the caveolae-disrupting agent cyclodextrin (CD; 5 mM, 60 min) or filipin (2.5 g/ml, 10 min). Src Y416 phosphorylation was caveolae independent (n ϭ 6). *P Ͻ 0.05 vs. control. C: pretreatment with the specific Src inhibitor SU-6656 (SU; 10 M, 30 min) before treatment with HG for 1 h blocked Cav-1 phosphorylation of Y14 (n ϭ 5). *P Ͻ 0.05, HG-treated group vs. the other groups. D: HGinduced PKC-␤1 membrane translocation was blocked by SU (n ϭ 5). *P Ͻ 0.05, HG-treated group vs. the other groups. E: HG induced an association of PKC-␤1 and Cav-1 that was prevented by SU (n ϭ 4). *P Ͻ 0.05, HG-treated group vs. the other groups. F: total Src protein levels and Src Y416 phosphorylation by HG were not affected by PKC-␤1 RNAi (n ϭ 4). *P Ͻ 0.05 vs. control.
prevented HG-induced Akt phosphorylation. As shown in Fig.  5B , the PKC-␤-specific inhibitor LY-333531 and the Srcspecific inhibitor SU-6656 blocked the association of caveolin-1 with Akt phosphorylation of S473. However, Akt phosphorylation of T308 was Src independent. These results suggest that Src is involved in HG-induced Akt phosphorylation of S473 by PKC-␤1.
We next used the nonphosphorylatable mutant caveolin-1 Y14A. MCs were transfected with EGFP-tagged caveolin-1 Y14A; overexpression of this construct is shown in Fig. 5C . As shown in Fig. 5D , Akt phosphorylation of S473 in response to HG, which was observed in MCs overexpressing the empty vector pEGFP-C1, was clearly abrogated in MCs with caveolin-1 Y14A. These data indicate that Src-mediated phosphorylation of caveolin-1 of Y14 is required for HG-induced Akt activation.
Src activation and caveolin-1 phosphorylation mediate RhoA activation. We (39, 40, 61) have previously shown that phosphorylation of caveolin-1 on Y14 by Src kinases is an upstream event in TGF-␤-, VEGF-, or mechanical stretchinduced RhoA activation in MCs. We thus determined whether caveolin-1 Y14 phosphorylation plays a role in HG-induced RhoA activation. As shown in Fig. 6A , RhoA activation in response to HG, which was observed in MCs overexpressing the empty vector pEGFP-C1, was completely inhibited in MCs with caveolin-1 Y14A. We next assessed the effects of the Src-specific inhibitor SU-6656 on RhoA activation. Figure 6B shows that SU-6656 prevented HG-induced RhoA activation. These data suggest that Src-mediated phosphorylation of caveolin-1 on Y14 enables RhoA activation after HG treatment.
HG-induced fibronectin upregulation requires Src activation and caveolin-1 phosphorylation. We (59, 60) have previously shown that collagen I induction by HG requires the activation of PKC-␤1 and Akt. We further confirmed the effect of PKC-␤1 and Akt on fibronectin protein levels in MCs. As shown in Fig. 7A , the PKC-␤-specific inhibitor LY-333531 and the phosphatidylinositol 3-kinase inhibitor wortmannin suppressed HG-induced fibronectin upregulation in MCs. Fibronectin upregulation was also blocked by LY-333531 in the kidney cortex of rats with type 1 diabetes induced by STZ injection (Fig. 7B) . We next investigated the role of Src kinases and caveolin-1 Y14 in matrix production. Figure 7C shows that the Src inhibitor SU-6656 prevented HG-induced fibronectin upregulation. Transfection with nonphosphorylatable mutant caveolin-1 Y14A in MCs also prevented fibronectin upregulation in response to HG (Fig. 7D) , suggesting that Src-mediated phosphorylation of caveolin-1 on Y14 is required for HGinduced extracellular matrix protein accumulation.
DISCUSSION
Under HG conditions, mesangial cells synthesize extracellular matrix proteins, including collagen and fibronectin, and glomerular matrix accumulation is the pathological hallmark of diabetic nephropathy (16, 32, 49) . Akt and RhoA signals have been implicated in the development of glomerular matrix accumulation (38, 60) . However, little is known regarding the upstream events. Our study now identifies a novel role for caveolin-1 phosphorylation in HG-induced Akt and RhoA activation. Our work also shows that Src kinase mediates the PKC-␤1/caveolin-1 association, PKC-␤1 membrane translocation, and caveolin-1 Y14 phosphorylation in response to HG in MCs. These data suggest that Src-mediated caveolin-1 phosphorylation may play an important role in diabetic renal disease.
PKC-␤ has been implicated in the pathogenesis of diabetic nephropathy. TGF-␤ upregulation and matrix accumulation in diabetic glomeruli or kidneys were prevented by either PKC-␤ inhibition or PKC-␤ deletion (1, 34, 37) . It has been previously reported that caveolae/caveolin-1 are required for PKC-␤1 and RhoA activation by HG in MCs (65); however, whether HG and PKC-␤1 activation regulate caveolin-1 expression and phosphorylation are currently unknown. Our data show, for the first time, that HG induced a time-dependent increase in caveolin-1 phosphorylation of Y14 in MCs. Using a PKC-␤-specific inhibitor and PKC-␤1 siRNA, our results show that PKC-␤1 activation was involved in HG-induced caveolin-1 phosphorylation of Y14, although the caveolin-1 protein level was not affected by PKC-␤ inhibition. PKC-␤ inhibition with LY-333531 also prevented the increased caveolin-1 phosphorylation in diabetic kidneys, supporting an important role of PKC-␤1 in caveolin-1 phosphorylation in in vitro studies. Fig. 7 . HG-induced fibronectin upregulation requires PKC-␤1 activation and Cav-1 Y14 phosphorylation. A: the effect of pretreatment with LY and the phosphatidylinositol 3-kinase inhibitor wortmannin (Wort) on HG-induced fibronectin protein expression at 6 h was assessed by Western blot analysis (n ϭ 5). Man, mannitol. *P Ͻ 0.05, HGtreated group vs. the other groups. B: type 1 diabetic Sprague-Dawley rat kidney cortexes were analyzed 4 wk after the onset of diabetes. One group was treated with LY. Fibronectin protein levels were assessed by Western blot analysis of cortical protein (n ϭ 8). *P Ͻ 0.05, STZ-treated group vs. the other groups. C: the effect of pretreatment with SU on HG-induced fibronectin protein expression at 6 h was assessed by Western blot analysis (n ϭ 5). *P Ͻ 0.05, HG-treated group vs. the other groups. D: HG-induced fibronectin upregulation was assessed at 6 h in MCs overexpressing Cav-1 Y14A compared with MCs with empty vector pEGFP-C1 (n ϭ 4). *P Ͻ 0.05 vs. control pEGFP-C1.
Given that Src family kinases and Abl (a substrate of Src) are the main caveolin-1 Y14 kinases (7, 10, 29, 47, 48) , we went on to assess the role of Src kinases in PKC-␤1-mediated caveolin-1 phosphorylation. Our data confirmed the Src activation induced by HG, which is independent of caveolae. Using the Src-specific inhibitor SU-6656 and PKC-␤1 siRNA, our data suggest that HG-induced Src activation in MCs may mediate PKC-␤1/caveolin-1 association and PKC-␤1 membrane translocation, which then assists in caveolin-1 phosphorylation by Src kinase. PKC-␤ inhibition with LY-333531 prevented PKC-␤1 membrane translocation but not the association between PKC-␤1 and caveolin-1, indicating that the PKC-␤1/caveolin-1 association is upstream of PKC-␤1 activation. This is consistent with Zhang et al.'s results (65) showing that caveolae and caveolin-1 are required for PKC-␤1 activation.
On the other hand, the total protein level of caveolin-1 increased in HG-treated MCs and diabetic kidney cortexes, but it was not statistically significant. Moriyama et al. (35) observed that the expression of caveolin-1 was significantly increased in the glomeruli of patients with glomerular disease, including diabetic nephropathy. In contrast, it has been previously reported that in renal cortical membrane preparations (caveolin-1 was not detectable in cytosolic fractions), caveolin-1 protein expression significantly declined in moderately hyperglycemic diabetic rats (4 wk) compared with control rats. Intensive insulin therapy restored caveolin-1 expression to levels comparable with those in nondiabetic control rats (25) . It has been suggested that insulin acts as an important modulator of caveolin-1 expression and subcellular distribution in the diabetic kidney (9) , although the mechanisms remain unknown. The diabetic rats in our study also received a low dose of insulin to prevent ketonuria, which may have influenced the expression of caveolin-1.
Akt is an important mediator of matrix upregulation in response to numerous stimuli, including glucose (58, 62) . We have previously demonstrated that PKC-␤1 is an Akt S473 kinase in HG-treated MCs. TGF-␤1 transcriptional upregulation and collagen I induction require PKC-␤1/Akt signaling (59, 60) . However, whether PKC-␤1 activity requires some cofactors has not been examined. The present study highlighted an important role of caveolae and caveolin-1 in Akt S473 phosphorylation by PKC-␤1 in HG-treated MCs. Our data show that Akt S473 phosphorylation is prevented by chemical disruption of caveolae with cyclodextrin or filipin. Blockade of caveolin-1 phosphorylation by the Src-specific inhibitor SU-6656 or transfection with nonphosphorylatable mutant caveolin-1 Y14A in MCs prevented HG-induced Akt S473 phosphorylation. Our results further demonstrate that HG induces the association of caveolin-1 and phosphorylated Akt at S473, which was inhibited by SU-6656. Thus, caveolin-1 may function as a scaffolding protein recruiting PKC-␤1 and Akt, and Src-mediated phosphorylation of caveolin-1 on Y14 is also required for protein-protein interactions of caveolin-1 with these molecules. Akt S473 phosphorylation by PKC-␤1 in HG-treated MCs needs intact caveolae, with caveolin-1 and Src kinases as cofactors.
RhoA/Rho kinase activation is required in HG-induced matrix upregulation, and Rho kinase inhibitor fasudil prevented glomerular fibronectin upregulation, glomerular sclerosis, and proteinuria in diabetic rats (11, 22, 23, 24, 38) . However, the precise mechanism of RhoA activation by glucose is not clear. It has been previously demonstrated that caveolae and PKC-␤1 are required for HG-induced RhoA activation in MCs (65) . However, whether Src activation and caveolin-1 Y14 phosphorylation regulate RhoA activity has not been addressed. Our work further shows that caveolin-1 phosphorylation of Y14 by Src kinase is necessary for RhoA activation in response to HG. Both the Src-specific inhibitor SU6656 and overexpression of the nonphosphorylatable mutant caveolin-1 Y14A prevented RhoA activation mediated by PKC-␤1 in response to HG. These results are consistent with previous studies (39, 40, 46, 61) suggesting that Src-dependent caveolin-1 Y14 phosphorylation is an upstream event in mechanical stretch-, TGF-␤-, or VEGF-induced RhoA activation.
Taken together, our data suggest that HG-induced RhoA activation and Akt S473 phosphorylation by PKC-␤1 need Src kinase and subsequent caveolin-1 phosphorylation as cofactors in MCs, although we have not shown the correlations between Akt S473 phosphorylation and RhoA activation. Given that both RhoA activation and Akt S473 phosphorylation are dependent on Src kinases and caveolin-1 phosphorylation, a similar dependence of HG-induced fibronectin upregulation on Src/caveolin-1 signaling was expected and shown.
As shown in Fig. 8 , our study demonstrates that Src activation induced by HG mediates PKC-␤1/caveolin-1 association and PKC-␤1 membrane translocation, which assists in caveolin-1 phosphorylation by Src kinase. Caveolin-1 phosphorylation of Y14 is necessary for Akt S473 phosphorylation, RhoA activation, and downstream fibronectin upregulation. These findings present novel insights into the complexities of PKC-␤1 signaling and suggest potential targets of caveolin-1 phosphorylation for the treatment of diabetic kidney disease.
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